AUTOMATED PROCESS FOR A TISSUE ENGINEERED BLOOD VESSEL

Information

  • Research Project
  • 6072498
  • ApplicationId
    6072498
  • Core Project Number
    R43HL064462
  • Full Project Number
    1R43HL064462-01
  • Serial Number
    64462
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/15/2000 - 24 years ago
  • Project End Date
    11/15/2000 - 24 years ago
  • Program Officer Name
  • Budget Start Date
    5/15/2000 - 24 years ago
  • Budget End Date
    11/15/2000 - 24 years ago
  • Fiscal Year
    2000
  • Support Year
    1
  • Suffix
  • Award Notice Date
    5/11/2000 - 24 years ago

AUTOMATED PROCESS FOR A TISSUE ENGINEERED BLOOD VESSEL

Since 1970, the death rate for coronary heart disease has declined dramatically, due in part to the success of aggressive interventional techniques such as coronary arterial bypass graft (CABG). However, since patency rates for CABG decrease dramatically after 10 years, many patients require a secondary procedure. Due to previous harvest or peripheral vascular disease progression, suitable autologous (self) vessels may not be available. Since synthetic grafts have not been used successfully for coronary- arterial reconstruction, there is no clinical alternative for CABG candidates lacking autologous vessels. Conservative estimates suggest 50,000 Americans die annually due to the lack of suitable graft material. Recently, we have reported a technique to produce functional blood vessels from a small skin biopsy. These human tissue engineered blood vessels (TEBVs) are fully autologous, fully biological, and capable of withstanding 20-fold physiological blood pressure. The vessels are suturable and have been implanted successfully in animals. The objective of this research plan is to expedite the commercial availability of clinically relevant TEBVs (20 cm in length and 4-6 mm in diameter). Specifically, we will develop a bioreactor to automate critical steps in the fabrication process. Histological and mechanical properties of the TEBVs will be examined to optimize and validate this process. PROPOSED COMMERCIAL APPLICATIONS: The initial target market is critical CABG patients with no suitable graft donor sites and stenoses untreatable with PCTA or stents. Conservative estimates suggest the U.S. market is currently 50,000 candidate patients per year and growing exponentially. TEBVs may also fulfill the imperative clinical need for small diameter vessels for bypass in the peripheral circulation. The sheet based technology used for this project may provide a platform for other tissue engineering applications, including A-V shunts for dialysis, tendons, ligaments, heart valves, and three dimensional tissues with a built in capillary network.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    98880
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:98880\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CYTOGRAFT TISSUE ENGINEERING, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    NOVATO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94949
  • Organization District
    UNITED STATES